MA51846A - Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases - Google Patents
Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinasesInfo
- Publication number
- MA51846A MA51846A MA051846A MA51846A MA51846A MA 51846 A MA51846 A MA 51846A MA 051846 A MA051846 A MA 051846A MA 51846 A MA51846 A MA 51846A MA 51846 A MA51846 A MA 51846A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitors
- compounds used
- heterocyclic compounds
- heterocyclic
- kinase
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631437P | 2018-02-15 | 2018-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51846A true MA51846A (fr) | 2021-04-21 |
Family
ID=67542098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051846A MA51846A (fr) | 2018-02-15 | 2019-02-15 | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11174252B2 (enExample) |
| EP (1) | EP3752491A4 (enExample) |
| JP (1) | JP2021514359A (enExample) |
| KR (1) | KR20200131246A (enExample) |
| CN (1) | CN112334451A (enExample) |
| AU (1) | AU2019220746A1 (enExample) |
| BR (1) | BR112020015431A2 (enExample) |
| CA (1) | CA3089592A1 (enExample) |
| IL (1) | IL276509A (enExample) |
| MA (1) | MA51846A (enExample) |
| MX (1) | MX2020008559A (enExample) |
| SG (1) | SG11202007754UA (enExample) |
| WO (1) | WO2019161224A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019126731A1 (en) * | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| US20220281859A1 (en) * | 2019-08-14 | 2022-09-08 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| CN114502536A (zh) * | 2019-08-14 | 2022-05-13 | 诺维逊生物股份有限公司 | 作为激酶抑制剂的杂环化合物 |
| CN113244386A (zh) * | 2020-02-13 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗肿瘤中的用途 |
| IL296025A (en) * | 2020-03-02 | 2022-10-01 | Sironax Ltd | Proptosis inhibitors - diarylamine para-acetamides |
| WO2022078309A1 (zh) * | 2020-10-12 | 2022-04-21 | 上海海雁医药科技有限公司 | 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| US20220259195A1 (en) * | 2021-02-03 | 2022-08-18 | Nuvation Bio Inc. | Crystalline forms of a cyclin-dependent kinase inhibitor |
| KR20240005751A (ko) * | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| WO2022236253A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| WO2022236256A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| WO2022236255A2 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| WO2022236257A1 (en) * | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| CN113264920B (zh) * | 2021-05-10 | 2022-09-02 | 中国药科大学 | 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用 |
| WO2022261643A1 (en) * | 2021-06-09 | 2022-12-15 | Nuvation Bio Inc. | Treating cancers with a cyclin-dependent kinase inhibitor |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
| WO2023205892A1 (en) * | 2022-04-27 | 2023-11-02 | Risen (Suzhou) Pharma Tech Co., Ltd. | Cdk inhibitors and pharmaceutical uses thereof |
| AU2023263197A1 (en) * | 2022-04-29 | 2024-11-14 | Beigene , Ltd. | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors |
| KR20250044316A (ko) * | 2022-07-29 | 2025-03-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
| WO2024051702A1 (zh) * | 2022-09-05 | 2024-03-14 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
| EP4618755A1 (en) * | 2022-11-15 | 2025-09-24 | Larkspur Biosciences, Inc. | Inhibitors and degraders of pip4k protein |
| CN121443601A (zh) * | 2023-07-03 | 2026-01-30 | 英矽智能科技知识产权有限公司 | 作为cdk2/4/6抑制剂的取代的噻唑化合物及其使用方法 |
| WO2025247364A1 (zh) * | 2024-05-30 | 2025-12-04 | 山东先声生物制药有限公司 | 杂环化合物作为cdk抑制剂及其用途 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2002002643A0 (en) | 2000-03-06 | 2002-12-31 | Warner Lambert Co | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| CA2441733A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US7259161B2 (en) * | 2002-11-04 | 2007-08-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| CA2573573A1 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| WO2007024949A2 (en) | 2005-08-25 | 2007-03-01 | Schering Corporation | Alpha2c adrenoreceptor agonists |
| CA2727174A1 (en) | 2008-06-20 | 2010-01-21 | Jiangao Song | Aryl gpr119 agonists and uses thereof |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| WO2010071846A2 (en) | 2008-12-19 | 2010-06-24 | Afraxis, Inc. | Compounds for treating neuropsychiatric conditions |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| EP2580213A4 (en) | 2010-06-09 | 2013-12-25 | Afraxis Holdings Inc | 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
| WO2011156775A2 (en) | 2010-06-10 | 2011-12-15 | Afraxis, Inc. | 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| US20130252967A1 (en) | 2010-06-10 | 2013-09-26 | Afraxis, Inc. | 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| PE20130774A1 (es) | 2010-07-29 | 2013-06-26 | Rigel Pharmaceuticals Inc | Compuestos heterociclicos activadores de ampk y metodos para emplearlos |
| ES2525866T3 (es) | 2010-08-05 | 2014-12-30 | Temple University - Of The Commonwealth System Of Higher Education | 8-alquil-7-oxo-7,8-dihidropirido [2,3-d]pirimidina-6-carbonitrilos sustituidos en 2 y usos de los mismos |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| WO2013175415A1 (en) | 2012-05-23 | 2013-11-28 | Piramal Enterprises Limited | Substituted pyrimidine compounds and uses thereof |
| AR091876A1 (es) | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
| US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| ME03557B (me) | 2013-03-15 | 2020-07-20 | G1 Therapeutics Inc | Privremena zaštiтa normalnih ćelija током hemoterapije |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| WO2015115673A1 (en) | 2014-01-31 | 2015-08-06 | Ono Pharmaceutical Co., Ltd. | Fused imidazole compounds |
| DK3149008T3 (en) | 2014-05-28 | 2019-04-01 | Shanghai Fochon Pharmaceutical Co Ltd | Specific protein kinase inhibitors |
| WO2016015605A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| CN105294682B (zh) | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| CN111333627B (zh) | 2015-03-11 | 2024-09-13 | 正大天晴药业集团股份有限公司 | 作为抗癌药物的取代的2-氢-吡唑衍生物 |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN108699055B (zh) | 2015-12-13 | 2020-10-23 | 杭州英创医药科技有限公司 | 用作抗癌药物的杂环化合物 |
| CN108779117B (zh) | 2015-12-27 | 2021-08-31 | 重庆复创医药研究有限公司 | 一类激酶抑制剂 |
| WO2017133701A1 (en) | 2016-02-06 | 2017-08-10 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
| CN107286180B (zh) | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| CN107286134B (zh) | 2016-04-11 | 2019-04-12 | 上海勋和医药科技有限公司 | 2，4-二取代嘧啶衍生物作为cdk抑制剂及其应用 |
| PL3442947T3 (pl) | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
| EP3445765A4 (en) | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| KR102374033B1 (ko) | 2016-05-07 | 2022-03-14 | 상하이 포천 파마슈티컬 씨오 엘티디 | 특정 단백질 키나제 억제제 |
| RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| WO2018005865A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| EP3505519B1 (en) | 2016-11-11 | 2022-01-05 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines |
| WO2018113771A1 (en) | 2016-12-22 | 2018-06-28 | Betta Pharmaceuticals Co., Ltd | Benzimidazole derivatives, preparation methods and uses theirof |
| CN107382974B (zh) | 2017-06-08 | 2020-06-05 | 扬州市三药制药有限公司 | 一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用 |
| CN111989099A (zh) | 2018-01-29 | 2020-11-24 | 贝塔制药有限公司 | 作为cdk4和cdk6抑制剂的2h-吲唑衍生物及其治疗用途 |
| WO2019165204A1 (en) | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
| US12312346B2 (en) | 2018-06-27 | 2025-05-27 | Tufts Medical Center, Inc. | Pyridopyrimidine compounds and methods of their use |
| AU2019309909A1 (en) | 2018-07-23 | 2021-02-04 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use |
| MX2021000895A (es) | 2018-07-27 | 2021-08-24 | California Inst Of Techn | Inhibidores de cinasas dependientes de ciclinas (cdk) y usos de los mismos. |
| CN110835334B (zh) | 2018-08-16 | 2022-10-18 | 中国药科大学 | 吲哚取代唑类化合物及其用途 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| CN113166105B (zh) | 2018-11-30 | 2024-11-08 | 杭州英创医药科技有限公司 | 作为cdk-hdac双通路抑制剂的杂环化合物 |
| CN113166110B (zh) | 2018-12-12 | 2023-08-11 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
-
2019
- 2019-02-15 JP JP2020543494A patent/JP2021514359A/ja active Pending
- 2019-02-15 SG SG11202007754UA patent/SG11202007754UA/en unknown
- 2019-02-15 BR BR112020015431-8A patent/BR112020015431A2/pt not_active Application Discontinuation
- 2019-02-15 MA MA051846A patent/MA51846A/fr unknown
- 2019-02-15 WO PCT/US2019/018244 patent/WO2019161224A1/en not_active Ceased
- 2019-02-15 US US16/277,355 patent/US11174252B2/en not_active Expired - Fee Related
- 2019-02-15 AU AU2019220746A patent/AU2019220746A1/en not_active Abandoned
- 2019-02-15 KR KR1020207026424A patent/KR20200131246A/ko not_active Withdrawn
- 2019-02-15 CN CN201980025159.XA patent/CN112334451A/zh active Pending
- 2019-02-15 CA CA3089592A patent/CA3089592A1/en active Pending
- 2019-02-15 EP EP19754726.8A patent/EP3752491A4/en not_active Withdrawn
- 2019-02-15 MX MX2020008559A patent/MX2020008559A/es unknown
-
2020
- 2020-08-05 IL IL276509A patent/IL276509A/en unknown
-
2021
- 2021-10-01 US US17/449,779 patent/US20230062022A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190248774A1 (en) | 2019-08-15 |
| US20230062022A1 (en) | 2023-03-02 |
| CA3089592A1 (en) | 2019-08-22 |
| CN112334451A (zh) | 2021-02-05 |
| MX2020008559A (es) | 2021-01-08 |
| SG11202007754UA (en) | 2020-09-29 |
| EP3752491A4 (en) | 2021-12-01 |
| KR20200131246A (ko) | 2020-11-23 |
| WO2019161224A1 (en) | 2019-08-22 |
| EP3752491A1 (en) | 2020-12-23 |
| IL276509A (en) | 2020-09-30 |
| JP2021514359A (ja) | 2021-06-10 |
| US11174252B2 (en) | 2021-11-16 |
| AU2019220746A1 (en) | 2020-08-27 |
| BR112020015431A2 (pt) | 2020-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
| MA52360A (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| FR24C1009I2 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| MA49956A (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| EP3997087A4 (en) | SUBSTITUTED CONDENSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THEIR USE | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA53487A (fr) | Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met | |
| MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| EP3873468A4 (en) | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | |
| MA53220A (fr) | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase | |
| EP3733671A4 (en) | AMINOFLUOROPERIDINE DERIVATIVES AS KINAS INHIBITOR | |
| EP3733673A4 (en) | OXY-FLUORPIPERIDE DERIVATIVES AS KINAS INHIBITOR | |
| EP3768661A4 (en) | DEUTERATED COMPOUNDS AS ROCK INHIBITORS | |
| EP3952865A4 (en) | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS FOR THERAPEUTIC USES | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA47099A (fr) | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs | |
| EP3750880A4 (en) | Pyrazine-2(1h)-ketone compound acting as fgfr inhibitor | |
| EP3697787A4 (en) | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | |
| MA54378A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |